Recordati Founding Family Sells €3bn Stake As PE Digs Deeper Into Pharma
Executive Summary
With private equity interest in the health space booming, CVC has taken a controlling stake in Recordati for €3.03bn, at a sharp discount to the Italian company’s share price.
You may also be interested in...
Recordati's Isturisa Approved For Cushing's In EU
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.